title: [Comparison of maternal and perinatal outcomes in the conservative treatment preterm premature membrane rupture between the use of erythromycin and clindamycin].
abstract: BACKGROUND
  premature rupture of membranes occurs between 5 and 15% of pregnancies, of these, 10% occurs at term and preterm 2 to 3.5%.
  
  
  OBJECTIVE
  To compare maternal and perinatal outcomes from the use of erythromycin or clindamycin in women with preterm premature rupture of membranes with conservative treatment at the Regional General Hospital No. 36.
  
  
  METHODS
  comparative, prospective, randomized study conducted at the Regional General Hospital No. 36 of the Instituto Mexicano del Seguro Social, Puebla. The most common risk factors were cervical infections (55%) and urinary tract infection (55%). A history of premature rupture of membranes in pregnancy was reported in 12.5% of patients. Group A was prescribed erythromycin and group B, standard-dose clindamycin, these were the independent variables. Maternal outcomes (deciduoendometritis and chorioamnionitis) and perinatal (respiratory distress syndrome, necrotizing enterocolitis and sepsis) were the dependent variables. Fisher exact test was applied to the results of the study.
  
  
  RESULTS
  about perinatal outcome, sepsis was expressed more frequently in the clindamycin group (60%) compared with erythromycin (35%). The occurrence of respiratory distress syndrome was similar in both groups, 70 and 75% respectively. For necrotizing enterocolitis, 25 and 5%. Maternal alterations as chorioamnionitis occurred in 20% of patients in group A and 5% in group B. Endometritis results were similar in both groups.
  
  
  CONCLUSIONS
  comparing the maternal and perinatal outcomes with conservative management of premature rupture of membranes, results were better in the group treated with erythromycin. It is not possible to prove it statistically because of the sample size.
authors.affiliation: Departamento de Estudios de Posgrado de la Benemérita Universidad Autónoma de Puebla.
authors.forename: Ariadna
authors.initials: A
authors.lastname: Hernández y Ballinas
authors.forename: Jose Angel
authors.initials: JA
authors.lastname: López Farán
authors.forename: Catalina
authors.initials: C
authors.lastname: Gámez Guevara
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002821:Chorioamnionitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002981:Clindamycin / Q000627:therapeutic use*; D004716:Endometritis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D020345:Enterocolitis, Necrotizing / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D007752:Obstetric Labor, Premature; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012127:Respiratory Distress Syndrome, Newborn / Q000453:epidemiology; D012307:Risk Factors; D018805:Sepsis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy; D002575:Uterine Cervicitis / Q000150:complications / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin; D004917:Erythromycin